SignalHF vs EchoNext
AI Verdict
Choose SignalHF if…
Choose SignalHF if you are managing heart failure patients with existing cardiac implantable electronic devices (CIEDs) and need a proactive tool to predict hospitalizations. This AI algorithm analyzes data from various CIEDs, including pacemakers, ICDs, and CRTs, to identify patients at high risk of heart failure hospitalization within 30 days, enabling early intervention and personalized care plans.
View SignalHF →Choose EchoNext if…
Choose EchoNext if you need a non-invasive, accessible screening tool to detect hidden structural heart disease in a broad patient population using standard ECGs. This AI-powered tool is particularly well-suited for identifying patients who should be evaluated for conditions like heart failure, valve disease, and pulmonary hypertension, even before symptoms present, thereby guiding further diagnostic steps like echocardiograms.
View EchoNext →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
SignalHFSignalHF is designed to integrate with existing cardiac implantable electronic devices (CIEDs) and provides automatic alerts, streamlining workflow for care teams. EchoNext is deployed through a clinical decision support platform, which may require additional steps for integration and use within existing clinical workflows.
Clinical Value
EchoNextEchoNext has demonstrated superior accuracy in detecting structural heart disease from ECGs compared to cardiologists, even when cardiologists were assisted by AI. It also has a broader detection capability, identifying a range of SHDs beyond just heart failure. SignalHF focuses specifically on predicting heart failure hospitalizations within 30 days.
Pricing & Value
EchoNextEchoNext provides transparent tiered pricing starting at $600/month, allowing potential users to understand costs upfront. SignalHF's pricing is 'contact for pricing,' which lacks transparency and makes it difficult to assess its value proposition without direct engagement.
Enterprise Readiness
TieBoth tools are FDA-cleared and HIPAA compliant, indicating a strong foundation for enterprise use. SignalHF offers manufacturer-agnostic compatibility with various CIEDs, while EchoNext is available through a widely used clinical decision support platform, suggesting both have mechanisms for broad deployment and integration within healthcare systems.
Innovation
EchoNextEchoNext represents a significant innovation by being the first FDA-approved AI tool to detect hidden structural heart disease from standard ECGs, outperforming cardiologists in diagnostic accuracy. SignalHF is innovative in its manufacturer-agnostic prediction of heart failure hospitalizations from CIED data, but EchoNext's ability to uncover a broader range of undiagnosed conditions from a common, inexpensive test is arguably more groundbreaking for widespread screening.
Support & Docs
TieNeither tool provides specific details about their support services or documentation in the provided information or through web searches. Therefore, it is not possible to definitively pick a winner in this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | SignalHF | EchoNext |
|---|---|---|
| Tool Name | SignalHF | EchoNext |
| Company | Implicity | Pathway Labs |
| Description | FDA-cleared AI algorithm that predicts heart failure hospitalizations within 30 days by analyzing data from various cardiac implantable electronic devices, enabling early intervention and personalized care. | FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension. |
| Key Functionality | Predicts heart failure hospitalizations within 30 days by analyzing CIED data. | Analyzes standard ECGs to detect hidden structural heart disease (heart failure, valve disease, pulmonary hypertension). |
| Data Source | Various cardiac implantable electronic devices (CIEDs) | Standard 12-lead ECGs |
| Specialties | Cardiology | Cardiology, Family Medicine, Hospital Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring SignalHF and EchoNext.